See the announcement on PR Newswire

"The Immunitas team is uniquely positioned to identify novel therapeutic oncology targets using their innovative single cell genomics-based techniques. Pairing the Immunitas platform with efficient discovery of highly diverse panels of antibodies will result in the rapid identification of therapeutic-quality antibodies," commented Tracey Mullen, CEO of Abveris. "Our function-forward approach to antibody discovery will enable Abveris to deliver fully validated drug candidates in accelerated timelines. Ultimately, the synergy between the two platforms will result in faster delivery of targeted therapies to the patients who need them."    

"We are excited to collaborate with Abveris to accelerate the pace of discovery for some of our new antibody therapeutics," said Jeff Goldberg, CEO of Immunitas. "Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations."

 

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Find additional information about Abveris at www.ABVERIS.com.

 

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

When a leader has the innate ability to help those around them become better, stronger all while focusing on the future, those abilities are rewarded.

That is why, effective today, Tracey Mullen will take over as Chief Executive Officer of Abveris. This change allows me to focus more on strategic partnerships and business development as Chief Business Officer. This decision was entirely my -own and, as the primary business owner of Abveris, a choice I believe is the right direction for our company.

During Tracey’s tenure at Abveris she has been responsible for increasing our average monthly revenue by 160%, more than doubling our company headcount, and co-leading the implementation of the Beacon B cell screening platform. A native of Connecticut, she earned her Bachelor’s Degree in Chemical-Biological Engineering from Massachusetts Institute of Technology (MIT), and her Executive Masters of Business Administration from Quantic School of Business and Technology.

Abveris is a scientific company and should be led by an elite scientist. With a strong focus on cutting-edge science and engineering, we at Abveris have the ability to change the future of medicine. We are now on a path to ensure this is our legacy. As we move out of the startup stage it is time for a new leader who has the skills I deem most valuable for our future: scientific knowledge, operational excellence, and courage.

Tracey is the most capable, talented, courageous and emotionally intelligent professional I have ever had the opportunity to know. She has earned the respect of everyone on our team and every one of our partners.  She is one of those rare leaders who makes everyone around her stronger and better — the rising tide that lifts all boats, not just a select few.

She is a glowing example of the next generation of leadership: a combination of subject matter expertise and sharp business acumen. There is a significant yet rare advantage in a leader like Tracey, who possesses an extensive understanding of our industry’s business operations as well as the intricate, technical details of our company’s work on the front lines.

I believe that a CEO should be the personification of her company’s brand. Tracey is Abveris personified: smart, hardworking, science-forward, deeply committed to success and fiercely competitive. I can’t think of a better embodiment of our premium, elite, yet approachable brand. Abveris has worked for years to hone the right brand, in the right market, with the right offering at the right time. Now that we have the right leader for the next phase of our company growth, we will move with more precision toward the opportunities that await us. 

Our business is, and has always been, to make quality biologic drugs. The antibodies we deliver will help cure disease and increase the quality of life globally. It is imperative that we continue to push ourselves as an organization to do the best job we possibly can so we can help make the world a better, healthier place. With Tracey making organization-wide decisions, Abveris will continue successfully fulfilling our mission to deliver the next generation of life-saving therapies.

In health and to our future,

Garren Hilow

Chief Business Officer, Creator, Owner

Click here to see the press release on BusinessWire.

Canton, MA, USA – Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon^®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse^®, an industry-leading transgenic mouse R&D platform. 

“We have worked with the Trianni Mouse across several therapeutic antibody programs and have been impressed with the success of these campaigns,” commented Colby Souders, Ph.D., Chief Scientific Officer of Abveris. “Abveris is uniquely positioned to dramatically shorten therapeutic discovery timelines while enhancing candidate selection by pairing optimized immunization methods in the Trianni Mouse with high-resolution single B cell screening enabled by the Berkeley Lights Beacon.”    

“We believe this partnership brings together powerful discovery technologies with the potential for accelerating Nkarta’s pipeline of natural killer cell therapy candidates,” said James Trager, Ph.D., Chief Scientific Officer of Nkarta. “We look forward to working closely with the Abveris team on the identification of targeted antibodies ideally suited for our cell engineering and manufacturing platform.”

“The Nkarta team is situated to redefine the way we think about cell therapies, and we are delighted to be working with their team of impassioned scientists,” added Tracey Mullen, MBA, Chief Operating Officer of Abveris. “This partnership highlights our continued commitment to working with organizations leveraging antibody therapeutics in innovative and transformative ways.” 

"We at Trianni are thrilled that the partnership of Abveris and Nkarta includes the use of the Trianni Mice. It is gratifying to contribute to the program of creating novel antibody therapeutics," said Matthias Wabl, Ph.D., Chief Executive Officer of Trianni, Inc.

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Trianni, Inc: 

Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. Trianni’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. Trianni’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about Trianni is available through its corporate website, www.TRIANNI.com.

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

Contact for Trianni:

Elizabeth Tran

Marketing manager

elizabeth.tran@trianni.com

(415) 231-0257

Abveris, Inc. 

March 18, 2020

RE: Staying Open for Science, COVID Response

To Our Valued Customers & Partners,

The COVID outbreak has caused significant disruptions to the science community worldwide, and your ongoing antibody discovery projects shouldn’t cause additional stress. Abveris will remain open for business and continue to provide contract research services during the state of emergency even if a "shelter-in-place" order is called. 

Abveris has multiple ongoing projects that directly contribute to drug development efforts for underserved diseases and indications (including COVID-19 and multiple other viral agents). Our end-to-end antibody discovery services are fully operational and we’re accepting new hybridoma and B cell screening discovery projects. Are you delaying your discovery work because of COVID-related antigen production delays? We can help.

Schedule 15 minutes with us today to discuss your project.

We are closely monitoring communications from the Massachusetts State and Federal Governments regarding measures to prevent the spread of the virus. Abveris has implemented mandatory work-from-home policies for non-essential staff, and employee schedules have been adjusted to promote social distancing. 

We welcome you to lean on us during these turbulent times. As always, we look forward to supporting your science.

Sincerely,

Garren Hilow

CEO of Abveris

Adversity has the effect of eliciting talents,

which in prosperous circumstances would have lain dormant

- Horace

Canton, MA, USA – August 12, 2019 – Boston-based antibody discovery services company Abveris has partnered with Biomatters to incorporate the Geneious Biologics data analysis platform into their antibody discovery workflow. In collaboration, a new Single Clone Antibody Annotator pipeline has been developed.

With a rapidly growing customer base and a wide range of antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as a premium hub for bioinformatics and computer programming capabilities.

"The Geneious team has done an excellent job accommodating our specific data resulting in a streamlined, high-throughput workflow that produces accurate data and operates efficiently without the need to integrate multiple bioinformatics platforms," remarked Dr. Colby Souders, Chief Technology Officer at Abveris. "We look forward to continuously improving the platform and its integration into our workflow to combine sequence analytics with metadata and assay data to accelerate candidate selection."

The Geneious team worked closely with Abveris to optimize and enhance the handling of their antibody NGS data. Jannick Bendtsen, VP Technology Services at Geneious, commented, "Abveris is at the cutting edge of antibody drug discovery; they are pushing the boundaries of science and technology. To have Colby and the team select Geneious Biologics is a great honor and a great compliment. We collaborated to integrate our Single Clone Antibody Annotator Pipeline, and it now runs out of the box. It's all about speed and accuracy in the discovery process."

About Abveris: Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at https://www.abveris.com.

About Geneious and Biomatters: Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering, and advanced comparative analysis of DNA, RNA, and protein sequences. Geneious solutions are created from a deep understanding of customer experience to turn the difficult into the intuitive and easy. Geneious is trusted by over 4,000 companies, universities, and institutes all over the globe. Additional information about Geneious is available at https://www.geneious.com.

Canton, MA, July 29, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced that it has entered into a collaborative agreement with Lava Therapeutics BV, a biopharmaceutical company developing next-generation T cell engager therapies. Under the terms of the agreement, Abveris will leverage its proprietary technology to develop critical reagent antibodies to support assay development for bispecific antibody γδ T cell engagers selected by Lava Therapeutics.

“The Abveris team is pleased to be working with Lava to accelerate the path to clinical development for their lead compound,” commented Ryan Kelly, Director of Business Development at Abveris. “We apply our proprietary hyperimmune platform to deliver consistent results for diverse biotherapeutic molecule formats. We look forward to working with the Lava Therapeutics team to help advance their γδ T cell engaging bispecific molecules.”

“We are delighted to enter a collaboration with Abveris on the generation of high-quality antibodies as critical reagents in our drug development programs of bispecific γδ T cell engagers. The use of the Abveris hyperimmune platform will enable the accelerated development of advanced (non-)clinical assays for our programs.” said Ton Adang, Senior VP and CDO of Lava Therapeutics B.V.

About Abveris:

Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About Lava Therapeutics:

Lava Therapeutics’ proprietary platform is focused on developing next-generation γδ T cell engaging bispecific antibodies to treat cancer. Lava’s vision is to develop therapeutics for the curative treatment of cancer. For more information, please visit www.lavatherapeutics.com.

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

+1 781-562-1170

Contact for Lava Therapeutics:

Erik Ensing

e.ensing@lavatherapeutics.com

Click here to read the press release on Business Wire.

Canton, MA, USA, Cambridge, MA, USA, and Rotterdam, the Netherlands, July 1, 2019 - Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, today announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform. The combined offering eliminates the need for antibody humanization through the use of the H2L2 Harbour Mice™, and benefits from Abveris’ full suite of therapeutic antibody discovery capabilities.

Abveris was selected as a designated CRO to offer its fully-human antibody discovery service under the Co-Offering Agreement utilizing the H2L2 Harbour Mice™. The Co-Offering Agreement with Harbour includes a low-upfront evaluation fee and pre-negotiated commercial terms that Abveris can in turn provide to partners. The new Co-Offering allows Abveris clients to assess the H2L2 human transgenic mouse technology before committing to a full commercial license.

“We have historically generated potent, fully-human antibodies using the H2L2 Harbour Mice™. This program will allow us to continue to offer H2L2 antibody discovery with the elimination of contractual barriers for our biopharma partners seeking fully-human antibody discovery,” said Garren Hilow, CEO of Abveris. “We look forward to continuing our partnership with Harbour to use the H2L2 Harbour Mice™ in both our hybridoma platform and our AbX Biologics single B-cell discovery platform.”

“We are really excited about this Agreement which allows us to offer our partners access to this leading technology platform in the form of the H2L2 Harbour Mice™. It is an integral part of our strategy to build truly innovative products both in-house and with our partners, and the partnership with Abveris will further allow us to better fulfill unmet medical needs for patients worldwide,” said Jingsong Wang, MD, Ph.D., Chairman & CEO of Harbour BioMed.

Harbour’s patented H2L2 mouse platform provides antibody generation through a natural in vivo process, allowing for the generation of diversified, affinity-matured, human antibody repertoires. Harbour Mice™ licensees include over 40 multinational pharmaceutical, biotechnology, and academic institutions. Abveris will leverage this platform in combination with its own proprietary immunization and high-throughput characterization capabilities to provide a fully-human therapeutic antibody discovery offering to its growing customer base.

About Abveris:

Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com

Contact:
Ryan Kelly, MBA
Abveris, Inc.
480 Neponset Street, Suite 10B
Canton, MA 02021, USA
contact@abverisantibody.com

About Harbour Antibodies:

Harbour Antibodies H2L2 BV is a fully owned subsidiary of Harbour BioMed, a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases (www.harbourbiomed.com). Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties. For additional information, please visit www.harbourantibodies.com

Contact:
Jung Lee, Ph.D.
Harbour Antibodies
One Broadway
Cambridge, MA 02142, USA
Jung.Lee@harbourbiomed.com

Click here to read the press release on Business Wire.

Canton, MA, June 17, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced the deployment of the Berkeley Lights, Inc. Beacon® optofluidic platform for antibody discovery.

Concurrent with this announcement, Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services. AbX Biologics will partner with biopharma companies to provide premium contract research capitalizing on a combination of proprietary in vivo technologies and the Beacon platform. The full AbX Biologics solution is expected to launch in 2020, with beta collaborations beginning Q3 2019. Abveris will continue to provide critical reagent antibody discovery and other antibody-related services.

“We are committed to integrating new and innovative technologies to our expanding suite of antibody discovery capabilities in an effort to continue providing premium services for our partners. We believe that the pioneering technology of the Beacon platform in combination with our own cutting-edge discovery expertise will enable us to deliver development-ready candidates in industry-leading timelines,” said Tracey Mullen, Chief Operating Officer of AbX Biologics and Abveris.

The Beacon platform provides accelerated single-cell screening and high-resolution analysis to identify and isolate antigen-specific antibody-secreting cells in a single day. AbX Biologics will leverage this groundbreaking technology in combination with its proprietary immunization and high-throughput characterization capabilities to provide a streamlined, best-in-class therapeutic antibody discovery offering to its growing customer base.

“We are delighted that Abveris and AbX Biologics have selected the Beacon Platform and our Antibody Discovery workflow for their therapeutic antibody discovery programs,” said Dr. Eric Hobbs, CEO of Berkeley Lights. “Berkeley Lights is driven to help companies accelerate the discovery of the best cells for their unique programs. We believe our work with AbX Biologics will help speed its antibody discovery efforts by screening more potential drug candidates faster, reducing the time from target to high value lead, and ultimately delivering new therapies to market faster.”

About Abveris:

Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAbTM hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com

About Berkeley Lights:

Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes workflows and processes for the biotechnology sector to accelerate the design, discovery, development, and delivery of cell-based products. By operating at the intersection of biology, technology and information, our workflows automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. BLI enables the rapid deployment of biology for the production of sustainable and scalable sources of food, therapies, and energy.

The Beacon platform is for Research Use Only. Not for use in diagnostic procedures.

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

781-562-1170

Click here to read the press release on Business Wire.

Canton, MA, June 4, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced that it has entered into a multi-target agreement with TetraGenetics, Inc. a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders. Under the terms of the agreement, the companies will leverage their proprietary technologies to discover antibodies against traditionally difficult ion channel targets chosen by TetraGenetics.

"We are pleased to be working with TetraGenetics to develop antibodies against some of the most elusive therapeutic targets," commented Garren Hilow, CEO of Abveris. "The combined benefits of our proprietary hyperimmune platform along with TetraGenetics' unique ion channel technology provide a significant competitive advantage for discovery of antibodies against this traditionally difficult target class.

For the collaboration, the TetraGenetics’ TetraExpress platform will be leveraged in combination with the proprietary antibody discovery capabilities of Abveris for the discovery of diverse panels of antibodies with therapeutic potential.

“As our newest antibody partner, Abveris brings unique technology and a reputation for excellent execution to our growing list of drug discovery programs,” said Doug Kahn, CEO of TetraGenetics.

About Abveris:

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About TetraGenetics:

TetraGenetics is focused on the discovery and development of first-in-class biologic medicines for autoimmune diseases, oncology and pain. The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins. TetraGenetics is actively building a proprietary drug pipeline and working collaboratively with major biotech companies for antibody drug discovery. For more information, please visit: www.tetragenetics.com.

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

781-562-1170

Contact for TetraGenetics:

Suzanne Gibbons-Neff

suzanne@sgnpr.com

203-858-1325